Phase 2 Pancreatic Cancer Trial, Recruiting NCT03498326 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT03498326
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who have had surgery that completely removed the cancer with no cancer cells left at the edges (called R0 resection)
  • People who have not previously been treated with a chemotherapy drug called gemcitabine for any cancer
  • People who are reasonably physically active and able to care for themselves, based on a standard performance scale (score of 0–2 on the ECOG scale)
  • People whose blood test results show healthy enough levels of white blood cells, platelets, and red blood cells (specific minimum levels required — confirm with trial site)
  • People whose liver and kidney function tests are within acceptable ranges (specific limits apply — confirm with trial site)

Who may not be able to join:

  • People whose pancreatic cancer is a specific type, such as endocrine carcinoma, acinar cell carcinoma, or cystadenocarcinoma
  • People whose surgery did not fully remove the cancer (did not meet R0 resection criteria)
  • People who received radiation therapy for pancreatic cancer before their surgery
  • People who have cancer that has spread to the brain
  • People who have a history of another serious cancer
  • People who have an active infection or severe diarrhoea
  • People who have a known allergy or intolerance to celecoxib (a drug used in this trial)
  • People who need to take aspirin or anti-inflammatory drugs (NSAIDs) on an ongoing basis
  • People who have had an allergic reaction, asthma, or hives after taking aspirin or anti-inflammatory drugs
  • People with a known allergy to sulfa drugs or similar chemical components found in the study drug
  • People who are pregnant or breastfeeding
  • People with an active stomach or bowel ulcer, bleeding, or perforation
  • People with a serious mental illness
  • People with severe heart failure
  • People with a history of serious cardiovascular (heart or blood vessel) clotting events, or severely uncontrolled high blood pressure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13666676128

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
2 April 2018
Est. completion
31 March 2023

Where this trial is recruiting

🇨🇳 China

Primary endpoints

disease free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov